We have read with great interest the meta-analysis performed by Qiu et al. [1] published in the European Journal of Internal Medicine, assessing the cardio-renal efficacy of different sodium-glucose co-transporter 2 (SGLT-2) inhibitors across major co-morbidities, namely type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF). Unfortunately, the authors did not address surrogate endpoints with SGLT-2 inhibitors use in patients with two or three kinds of diseases since the patient-level data were not available, as they state in their article.
